Thrombogenicity of Lipoprotein A
Research type
Research Study
Full title
Thrombogenicity of Lipoprotein A: a prospective, non – randomised, open label, proof of concept, laboratory study defining the prothrombotic effects of Lipoprotein A
IRAS ID
297224
Contact name
Pyotr Telyuk
Contact email
Sponsor organisation
South Tees NHS Foundation Trust
Duration of Study in the UK
1 years, 0 months, 17 days
Research summary
Lipoproteins are substances made of protein and fat that carry cholesterol around the bloodstream. Lipoprotein A (LPa) is an independent risk factor for development of stroke and heart attack. Traditionally the role of LPa has been linked to the plaque formation inside the arteries, a process called atherosclerosis. The evidence also suggests that LPa may play a role in the formation of larger amount of clot and more resistant blood clots by interfering with clotting process. This observation has an important implication in management of patients presenting with heart attacks, strokes and venous blood clots.
The main purpose of Thrombogenicity of LPa study is to assess the tendency of blood rich in LPa to form clots and to analyse the structure of the clot. The study will involve obtaining a blood sample from patients with a previous history of heart attack and performing multiple analysis on the blood samples in laboratory conditions using Badimon Perfusion Chamber which is a model used to assess formation of blood clot. The blood clots will be studied under specialized microscope called scanning electron microscope (SEM).
Thromboelastography is another method we will use to assess the efficiency of blood to form clots. The speed and strength of clot formation will be measured by a computer.REC name
London - Harrow Research Ethics Committee
REC reference
21/PR/1040
Date of REC Opinion
2 Sep 2021
REC opinion
Further Information Favourable Opinion